Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467272 · ClinicalTrials.gov registry record · Phase 2
Catheter Related - Gram Positive Bloodstream Infections
A Phase 2 study of Bloodstream Infection, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00467272 is a Phase 2 study of Bloodstream Infection that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 79-participant average among 3 other Bloodstream Infection trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00467272, a Phase 2 study of Bloodstream Infection, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: -Evaluate the clinical efficacy and safety of Daptomycin given for treatment of catheter-related bloodstream infections (CRBSI) due to gram positive bacteremia in the context of standard of care antimicrobial therapy consisting mainly of Vancomycin with or without initial treatment with beta lactam antibiotics.
Conditions Studied
Interventions
- DRUG Daptomycin
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467272
The ClinicalTrials.gov registry entry for NCT00467272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 3 other Bloodstream Infection trials with a reported enrollment target (62% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bloodstream Infection appearing as the primary indexed condition, and to 1 intervention - of which Daptomycin is the first listed.
NCT00467272 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00467272 about?
NCT00467272 is a clinical study titled "Catheter Related - Gram Positive Bloodstream Infections". Primary Objective: -Evaluate the clinical efficacy and safety of Daptomycin given for treatment of catheter-related bloodstream infections (CRBSI) due to gram positive bacteremia in the context of standard of care antimicrobial therapy consisting mainly of Vancomycin with or without initial treatme...
What is the current status of trial NCT00467272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-03. Estimated completion is 2012-09.
What conditions does trial NCT00467272 study?
This clinical trial studies the following conditions: Bloodstream Infection.
What interventions are being tested in trial NCT00467272?
The interventions under investigation include: Daptomycin (DRUG).
Who is sponsoring clinical trial NCT00467272?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00467272 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bloodstream Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
RECRUITING · NA
-
Next Generation Pathogen Sequencing for Prediction of Adverse Events
ACTIVE NOT RECRUITING
-
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.